GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioDelivery Sciences International Inc (FRA:BD5) » Definitions » Quality Rank

BioDelivery Sciences International (FRA:BD5) Quality Rank


View and export this data going back to 2004. Start your Free Trial

What is BioDelivery Sciences International Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

BioDelivery Sciences International Quality Rank Related Terms

Thank you for viewing the detailed overview of BioDelivery Sciences International's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


BioDelivery Sciences International (FRA:BD5) Business Description

Traded in Other Exchanges
N/A
Address
4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612
BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.